Literature DB >> 7231277

Informed consent: a medical viewpoint.

J S Simpson.   

Abstract

Clinical trials now have an established place in the evaluation of new cancer treatments. It is vital that there should be no conflict between the scientific aspects of clinical trials and the interests of patients with cancer. This conflict can be avoided if trial designs meet accepted standards, and if patients are able to make "informed" decisions abut participation. This process of obtaining informed consent is the subject of much debate. How the debate can be resolved by an individual clinician depends on his perception of a number of fundamental ethical principles. There is growing agreement, however, that regardless of the details of the process of obtaining informed consent, certain basic requirements must be met. The patient must be told that he is participating in a research procedure, that entry is optional, that withdrawal at any time is his right, and he must understand the nature of the trial and the likely effects of treatment, both good and bad.

Entities:  

Keywords:  Biomedical and Behavioral Research

Mesh:

Year:  1981        PMID: 7231277     DOI: 10.5694/j.1326-5377.1981.tb135436.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  Critical care research and pre-emptive informed consent: a practical approach used in Chris Hani Baragwanath ICU.

Authors:  M Pinder; S Tshukutsoane; J Scribante; R Piccolo; J Lipman
Journal:  Intensive Care Med       Date:  1998-04       Impact factor: 17.440

2.  Informed consent: ethical, legal, and medical implications for doctors and patients who participate in randomised clinical trials.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-02

3.  Cancer patients: their desire for information and participation in treatment decisions.

Authors:  H J Sutherland; H A Llewellyn-Thomas; G A Lockwood; D L Tritchler; J E Till
Journal:  J R Soc Med       Date:  1989-05       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.